{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:44Z","timestamp":1753891844959,"version":"3.41.2"},"reference-count":134,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pediatric diencephalic tumors represent a histopathologically and molecularly diverse group of neoplasms arising in the central part of the brain and involving eloquent structures, including the hypothalamic-pituitary axis (HPA), optic pathway, thalamus, and pineal gland. Presenting symptoms can include significant neurological, endocrine, or visual manifestations which may be exacerbated by injudicious intervention. Upfront multidisciplinary assessment and coordinated management is crucial from the outset to ensure best short- and long-term functional outcomes. In this review we discuss the clinical and pathological features of the neoplastic entities arising in this location, and their management. We emphasize a clear move towards \u2018function preserving\u2019 diagnostic and therapeutic approaches with novel toxicity-sparing strategies, including targeted therapies.<\/jats:p>","DOI":"10.3389\/fonc.2023.1178553","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:19:39Z","timestamp":1696943979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes"],"prefix":"10.3389","volume":"13","author":[{"given":"Julia V.","family":"Cockle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Corley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassel","family":"Zebian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Hettige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sucheta J.","family":"Vaidya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Jane","family":"Leitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry C.","family":"Mandeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Carceller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynley V.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"volume-title":"Nolte\u2019s the Human Brain an Introduction to its Functional Anatomy","year":"2020","author":"Vanderah","key":"B1"},{"key":"B2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/adc.47.253.338","article-title":"Diencephalic syndrome of infantile emaciation: analysis of literature and report of further 3 cases","volume":"47","author":"Addy","year":"1972","journal-title":"Arch Dis Child"},{"key":"B3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/s0090-3019(82)80043-8","article-title":"A diencephalic syndrome of emaciation in infancy and childhood","volume":"26","author":"Russell","year":"1951","journal-title":"Arch Dis Child"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3390\/children9111617","article-title":"Endocrine disorders in children with brain tumors: at diagnosis, after surgery, radiotherapy and chemotherapy","volume":"9","author":"Claude","year":"2022","journal-title":"Children (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/S41572-022-00351-Z","article-title":"Hypothalamic syndrome","volume":"8","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","article-title":"Craniopharyngioma","volume":"5","author":"M\u00fcller","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0709","article-title":"History before diagnosis in childhood craniopharyngioma: associations with initial presentation and long\u2013term prognosis","volume":"173","author":"Hoffmann","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.wneu.2020.05.172","article-title":"Craniopharyngiomas: challenges and controversies","volume":"142","author":"Asha","year":"2020","journal-title":"World Neurosurg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos142","article-title":"Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program","volume":"14","author":"Zacharia","year":"2012","journal-title":"Neuro Oncol"},{"volume-title":"Craniopharyngioma: Guideline for the management of children and young people (CYP) aged <19 years","year":"2021","key":"B10"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3171\/jns.1992.76.1.0047","article-title":"Aggressive surgical management of craniopharyngiomas in children","volume":"76","author":"Hoffman","year":"1992","journal-title":"J Neurosurg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","article-title":"Long\u2013term outcomes for surgically resected craniopharyngiomas","volume":"46","author":"Duff","year":"2000","journal-title":"Neurosurgery"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2018.01.029","article-title":"Comparing survival outcomes of gross total resection and subtotal resection with radiotherapy for craniopharyngioma: a meta\u2013analysis","volume":"226","author":"Wang","year":"2018","journal-title":"J Surg Res"},{"key":"B14","article-title":"Diabetes insipidus in craniopharyngioma: Postoperative management of water and electrolyte disorders","author":"Stefano","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/ped.2007.106.1.3","article-title":"Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement","volume":"106","author":"Puget","year":"2007","journal-title":"J Neurosurg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3171\/ped.2007.106.1.1","article-title":"Craniopharyngioma","volume":"106","author":"Boop","year":"2007","journal-title":"J Neurosurg Pediatr"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/S10143-018-1010-9","article-title":"Craniopharyngioma adherence: a reappraisal of the evidence","volume":"43","author":"Prieto","year":"2020","journal-title":"Neurosurg Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2022.5.JNS212974","article-title":"Endoscopic endonasal approach for infradiaphragmatic craniopharyngiomas: a multicentric Italian study","volume":"138","author":"Solari","year":"2022","journal-title":"J Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-019-04168-2","article-title":"The endoscopic endonasal approach for pediatric craniopharyngiomas: the key lessons learned","volume":"35","author":"d\u2019Avella","year":"2019","journal-title":"Child\u2019s Nerv Syst"},{"key":"B20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3171\/2017.7.PEDS17295","article-title":"Suprasellar and recurrent pediatric craniopharyngiomas: Expanding indications for the extended endoscopic transsphenoidal approach","volume":"21","author":"Alalade","year":"2018","journal-title":"J Neurosurg Pediatr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.05.174","article-title":"Current results of surgical treatment of craniopharyngiomas: the impact of endoscopic endonasal approaches","volume":"142","author":"Almeida","year":"2020","journal-title":"World Neurosurg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.10.030","article-title":"Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma","volume":"85","author":"Merchant","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26654","article-title":"Clinical outcomes following proton therapy for children with central nervous system tumors referred overseas","volume":"64","author":"Indelicato","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3171\/2009.9.PEDS09257","article-title":"Malignant transformation of irradiated craniopharyngioma in children: report of 2 cases","volume":"5","author":"Aquilina","year":"2010","journal-title":"J Neurosurg Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.3171\/2010.1.FOCUS09297","article-title":"Radiation therapy for pediatric craniopharyngioma","volume":"28","author":"Kiehna","year":"2010","journal-title":"Neurosurg Focus"},{"key":"B26","article-title":"Craniopharyngioma radiotherapy: endocrine and cognitive effects","author":"Merchant","year":"2006","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-022-04116-2","article-title":"Physical function, body mass index, and fitness outcomes in children, adolescents, and emerging adults with craniopharyngioma from proton therapy through five years of follow\u2013up","volume":"159","author":"Partin","year":"2022","journal-title":"J Neurooncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21530","article-title":"Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function","volume":"51","author":"Merchant","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22633","article-title":"Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience","volume":"109","author":"Hukin","year":"2007","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/neuonc\/nox056","article-title":"Intracystic interferon\u2013alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN","volume":"19","author":"Kilday","year":"2017","journal-title":"Neuro Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa119","article-title":"Phase II study of peginterferon alpha\u20132b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report","volume":"22","author":"Goldman","year":"2020","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011\u20132015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3171\/2010.1.FOCUS09315","article-title":"Intracystic treatments for craniopharyngioma","volume":"28","author":"Steinbok","year":"2010","journal-title":"Neurosurg Focus"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/S00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low\u2013grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low\u2013grade glioma","volume":"30","author":"Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18\u2013month treatment programme for childhood (\u226416 years) low grade glioma \u2013 A final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low\u2013grade gliomas: a prospective multi\u2013institutional study from the Children\u2019s Oncology Group","volume":"68","author":"Wisoff","year":"2011","journal-title":"Neurosurgery"},{"key":"B40","unstructured":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low\u2013Grade Glioma Requiring First\u2013Line Systemic Therapy2023"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac223","article-title":"A nationwide evaluation of bevacizumab\u2013based treatments in paediatric low\u2013grade glioma in the UK: safety. Efficacy, visual morbidity and outcomes","volume":"25","author":"Green","year":"2022","journal-title":"Neuro Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2217\/cns.12.47","article-title":"Optic pathway gliomas: a review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1997.215","article-title":"The clinical presentation of children with tumours affecting the anterior visual pathways","volume":"11","author":"Suharwardy","year":"1997","journal-title":"Eye"},{"key":"B44","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2017.06.019","article-title":"Clinical presentation and outcome of patients with optic pathway glioma","volume":"75","author":"Robert\u2013Boire","year":"2017","journal-title":"Pediatr Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J Child Neurol"},{"key":"B46","article-title":"Guidelines for the diagnosis and management of paediatric and adolescent Low\u2013Grade Glioma (extrapolated from current SIOP\u2013E\u2013BTG and GPOH Guidelines for Diagnosis and Treatment of Children and Adolescents with Low\u2013Grade Glioma: Klin Padiatr","volume":"231","author":"Bailey","year":"2019","journal-title":"Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/FOC-07\/11\/E2","article-title":"Optic pathway gliomas: a review","volume":"23","author":"Binning","year":"2007","journal-title":"Neurosurg Focus"},{"key":"B48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta\u2013analysis of 1,000 pediatric high\u2013grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00105","article-title":"Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology","volume":"2","author":"Fangusaro","year":"2012","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0611","article-title":"Open\u2013label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high\u2013grade glioma","volume":"36","author":"Grill","year":"2018","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28011","article-title":"Challenging the indiscriminate use of temozolomide in pediatric high\u2013grade gliomas: A review of past, current, and emerging therapies","volume":"67","author":"Guerra\u2013Garc\u00eda","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOW101","article-title":"Pediatric high\u2013grade glioma: biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neuro Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor045","article-title":"Thalamic high\u2013grade gliomas in children: a distinct clinical subset","volume":"13","author":"Kramm","year":"2011","journal-title":"Neuro Oncol"},{"volume-title":"The Cure Starts Now","year":"2021","key":"B55"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-015-2968-z","article-title":"Pediatric thalamic tumors in the MRI era: a Canadian perspective","volume":"32","author":"Steinbok","year":"2016","journal-title":"Childs Nerv Syst"},{"key":"B57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000028681","article-title":"Bithalamic involvement predicts poor outcome among children with thalamic glial tumors","volume":"29","author":"Reardon","year":"1998","journal-title":"Pediatr Neurosurg"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12484","article-title":"Bithalamic gliomas may be molecularly distinct from their unilateral high\u2013grade counterparts","volume":"28","author":"Broniscer","year":"2018","journal-title":"Brain Pathol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-020-04589-y","article-title":"Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas","volume":"163","author":"Dorfer","year":"2021","journal-title":"Acta Neurochir (Wien)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2017.10.132","article-title":"Prognostic factors for the survival outcome of bilateral thalamic glioma: an integrated survival analysis","volume":"110","author":"Niu","year":"2018","journal-title":"World Neurosurg"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab252","article-title":"EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults","volume":"24","author":"Frappaz","year":"2022","journal-title":"Neuro Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/0284186X.2011.586000","article-title":"Intracranial germ cell tumours. A review with special reference to endocrine manifestations","volume":"51","author":"Jorsal","year":"2012","journal-title":"Acta Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000370065","article-title":"Management of electrolyte and fluid disorders after brain surgery for pituitary\/suprasellar tumours","volume":"83","author":"Edate","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-022-03121-9","article-title":"Endocrine manifestations of paediatric intracranial germ cell tumours: from diagnosis to long\u2013term follow\u2013up","volume":"77","author":"Partenope","year":"2022","journal-title":"Endocrine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30168","article-title":"Implications of deferred diagnosis of paediatric intracranial germ cell tumours","volume":"70","author":"Partenope","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199903000-00007","article-title":"Late effects of treatment for germ cell tumors during childhood and adolescence","volume":"21","author":"Hale","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000496564","article-title":"Hypothalamic obesity: prologue and promise","volume":"91","author":"Jennifer Abuzzahab","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B68","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-013-1197-0","article-title":"Late causes of death in children treated for CNS malignancies","volume":"115","author":"Perkins","year":"2013","journal-title":"J Neurooncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou311","article-title":"Long\u2013term outcomes and late effects for childhood and young adulthood intracranial germinomas","volume":"17","author":"Acharya","year":"2015","journal-title":"Neuro Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-016-3157-4","article-title":"Pineal region tumors: a simplified management scheme","volume":"32","author":"Zaazoue","year":"2016","journal-title":"Childs Nerv Syst"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7462","article-title":"The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know","volume":"43","author":"Osborn","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOW234","article-title":"Evaluation of age\u2013dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP\u2013E) and US Head Start data","volume":"19","author":"Mynarek","year":"2017","journal-title":"Neuro Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac056","article-title":"Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data","volume":"4","author":"Hansford","year":"2022","journal-title":"Neurooncol Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26300","article-title":"The long\u2013term postsurgical prognosis of patients with pineoblastoma","volume":"118","author":"Tate","year":"2012","journal-title":"Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.096","article-title":"High\u2013dose chemotherapy with autologous stem\u2013cell rescue in children and adults with newly diagnosed pineoblastomas","volume":"21","author":"Gururangan","year":"2003","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2019.05.015","article-title":"Progress towards molecular\u2013based management of childhood Langerhans cell histiocytosis","volume":"26","author":"H\u00e9ritier","year":"2019","journal-title":"Arch Pediatr"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14140","article-title":"Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30\u2013year nationwide cohort of 1478 patients under 18 years of age","volume":"174","author":"Rigaud","year":"2016","journal-title":"Br J Haematol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279083","article-title":"Recurrent BRAF mutations in Langerhans cell histiocytosis","volume":"116","author":"Badalian\u2013Very","year":"2010","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033891","article-title":"B\u2013RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease","volume":"7","author":"Satoh","year":"2012","journal-title":"PloS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000304","article-title":"Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: Demonstration by allele\u2013specific PCR\/direct sequencing and immunohistochemistry","volume":"38","author":"M\u00e9hes","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-429597","article-title":"BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis","volume":"120","author":"Sahm","year":"2012","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430140","article-title":"High prevalence of BRAF V600E mutations in Erdheim\u2013Chester disease but not in other non\u2013Langerhans cell histiocytoses","volume":"120","author":"Haroche","year":"2012","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26104","article-title":"Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci","volume":"63","author":"Egeler","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.13247","article-title":"Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X","volume":"169","author":"Berres","year":"2015","journal-title":"Br J Haematol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work\u2013up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21498","article-title":"Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000\u20132004","volume":"51","author":"Guyot\u2013Goubin","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2007.06.003","article-title":"Endocrine manifestations in Langerhans cell histiocytosis","volume":"18","author":"Makras","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2003.12.030","article-title":"Endocrine involvement in pediatric\u2013onset langerhans\u2019 cell histiocytosis: a population\u2013based study","volume":"144","author":"Donadieu","year":"2004","journal-title":"J Pediatr"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.048","article-title":"Cognitive outcome of long\u2013term survivors of multisystem langerhans cell histiocytosis: a single\u2013institution, cross\u2013sectional study","volume":"21","author":"Nanduri","year":"2003","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/ADC.75.1.17","article-title":"A multicentre retrospective survey of Langerhans\u2019 cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans\u2019 Cell Histiocytosis Study Group","volume":"75","author":"Donadieu","year":"1996","journal-title":"Arch Dis Child"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.10006","article-title":"Securing access to innovative anticancer therapies for children, adolescents, and young adults outside clinical trials: The SACHA study of the French Society of Pediatric Oncology (SFCE)","volume":"40","author":"Berlanga","year":"2022","journal-title":"JCO"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1136","article-title":"The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies","volume":"12","author":"Berlanga","year":"2022","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw274","article-title":"Target and agent prioritization for the children\u2019s oncology group\u2013National Cancer Institute pediatric MATCH trial","volume":"109","author":"Allen","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1072-4","article-title":"Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high\u2013risk pediatric cancer","volume":"26","author":"Wong","year":"2020","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high\u2013evidence targets","volume":"11","author":"Van Tilburg","year":"2021","journal-title":"Cancer Discov"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0381","article-title":"Molecular screening for cancer treatment optimization (MOSCATO\u201301) in pediatric patients: A single\u2013institutional prospective molecular stratification trial","volume":"23","author":"Harttrampf","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.957944","article-title":"Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations","volume":"10","author":"Stankunaite","year":"2022","journal-title":"Front Pediatr"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0002-9440(10)64477-X","article-title":"Craniopharyngiomas of adamantinomatous type harbor \u03b2\u2013Catenin gene mutations","volume":"161","author":"Sekine","year":"2002","journal-title":"Am J Pathol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01799","article-title":"Small\u2013molecule inhibitors targeting the canonical WNT signaling pathway for the treatment of cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.14.4.505\/abstract","article-title":"Expression of interleukin\u20136 in human craniopharyngiomas: a possible inducer of tumor\u2013associated inflammation","volume":"14","author":"Mori","year":"2004","journal-title":"Int J Mol Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(20)30177-2","article-title":"COVID\u201319 in children and adolescents in Europe: a multinational, multicentre cohort study","volume":"4","author":"G\u00f6tzinger","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00791","article-title":"Targeting IL\u20136 is a potential treatment for primary cystic craniopharyngioma","volume":"9","author":"Grob","year":"2019","journal-title":"Front Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOAC079.057","article-title":"RARE\u201332. Phase 0 and feasibility single\u2013institution clinical trial of intravenous tocilizumab for adamantinomatous craniopharyngioma","volume":"24","author":"Dorris","year":"2022","journal-title":"Neuro Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1830-2","article-title":"Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target","volume":"135","author":"Apps","year":"2018","journal-title":"Acta Neuropathol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28753","article-title":"Radiologic response to MEK inhibition in a patient with a WNT\u2013activated craniopharyngioma","volume":"68","author":"Patel","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3171\/2019.10.FOCUS19705","article-title":"Adamantinomatous craniopharyngioma: moving toward targeted therapies","volume":"48","author":"Hengartner","year":"2020","journal-title":"Neurosurg Focus"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy035","article-title":"Multiplexed immunofluorescence reveals potential PD\u20131\/PD\u2013L1 pathway vulnerabilities in craniopharyngioma","volume":"20","author":"Coy","year":"2018","journal-title":"Neuro Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s11060\u2013020\u201303578\u20136","article-title":"Immune checkpoint inhibition for pediatric patients with recurrent\/ refractory CNS tumors: a single institution experience","volume":"149","author":"Cacciotti","year":"2020","journal-title":"J Neurooncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/NG.2611","article-title":"Whole\u2013genome sequencing identifies genetic alterations in pediatric low\u2013grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat Genet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00054","article-title":"Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low\u2013grade gliomas","volume":"5","author":"Penman","year":"2015","journal-title":"Front Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3922","article-title":"BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high\u2013grade glioma","volume":"33","author":"Mistry","year":"2015","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.18632\/oncotarget.27600","article-title":"Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro\u2013Oncology Consortium study (PNOC\u2013002)","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00298","article-title":"Outcomes of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition","volume":"4","author":"Nobre","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3572","article-title":"A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation\u2013positive solid tumors","volume":"25","author":"Kieran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation\u2013positive relapsed or refractory low\u2013grade glioma: results from a phase I\/IIa study","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600\u2013mutant low\u2013grade glioma","volume":"41","author":"Bouffet","year":"2022","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0000000000001427","article-title":"Trametinib toxicities in patients with low\u2013grade gliomas and diabetes insipidus: related findings","volume":"42","author":"Egan","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"LBA2002","DOI":"10.1200\/JCO20224017_supplLBA2002","article-title":"Primary analysis of a phase II trial of dabrafenib plus trametinib (dab + tram) in BRAF V600\u2013mutant pediatric low\u2013grade glioma (pLGG)","volume":"40","author":"Bouffet","year":"2022","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219232110","article-title":"Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas","volume":"110","author":"Sievert","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B120","doi-asserted-by":"publisher","first-page":"4","DOI":"10.17925\/OHR.2023.19.1.4","article-title":"Pan\u2013RAF inhibitors for paediatric low\u2013grade gliomas offer new opportunities in targeted therapy","volume":"19","author":"Ziegler","year":"2023","journal-title":"Oncol Haematol"},{"key":"B121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10062","article-title":"FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors","volume":"40","author":"Landi","year":"2022","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"crossref","first-page":"vii89","DOI":"10.1093\/neuonc\/noac209.333","article-title":"CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of PAN-RAF inhibitor Tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors","volume":"24","author":"Kilburn","year":"2022","journal-title":"Neuro Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1093\/NEUONC\/NOAA222.083","article-title":"DIPG\u201335. Biological medicine for diffuse intrinsic pontine glioma (dipg) eradication: results of the three arm biomarker\u2013driven randomized biomede 1.0 trial","volume":"22","author":"Grill","year":"2020","journal-title":"Neuro Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27389","article-title":"Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency","volume":"65","author":"Larouche","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02155-5","article-title":"Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition","volume":"139","author":"Mondal","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/neuonc\/noaa251","article-title":"A subset of pediatric\u2013type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR","volume":"23","author":"Sievers","year":"2021","journal-title":"Neuro Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_SUPPL.3617","article-title":"Clinical efficacy of ONC201 in thalamic H3 K27M\u2013mutant glioma","volume":"38","author":"Kawakibi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/NATURE13296","article-title":"Novel somatic and germline mutations in intracranial germ cell tumors","volume":"511","author":"Wang","year":"2014","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/jpm11070661","article-title":"Molecular pathology and targeted therapies for personalized management of central nervous system germinoma","volume":"11","author":"Ilcus","year":"2021","journal-title":"J Pers Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9508","article-title":"BRAF mutation correlates with high\u2013risk langerhans cell histiocytosis and increased resistance to first\u2013line therapy","volume":"34","author":"H\u00e9ritier","year":"2016","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147377","article-title":"Dabrafenib, alone or in combination with trametinib, in pediatric patients with BRAF V600 mutation\u2013positive langerhans cell histiocytosis","volume":"138","author":"Whitlock","year":"2021","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006229","article-title":"Development of BRAFV600E\u2013positive acute myeloid leukemia in a patient on long\u2013term dabrafenib for multisystem LCH","volume":"6","author":"Salek","year":"2022","journal-title":"Blood Adv"},{"key":"B134","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1200\/JCO.19.00456","article-title":"Vemurafenib for refractory multisystem langerhans cell histiocytosis in children: an international observational study","volume":"37","author":"Donadieu","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1178553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:19:48Z","timestamp":1696943988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1178553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":134,"alternative-id":["10.3389\/fonc.2023.1178553"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1178553","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"article-number":"1178553"}}